BioLargo Statistics
Total Valuation
BioLargo has a market cap or net worth of 31.85 million. The enterprise value is 35.18 million.
| Market Cap | 31.85M |
| Enterprise Value | 35.18M |
Important Dates
The next confirmed earnings date is Thursday, September 10, 2026.
| Earnings Date | Sep 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioLargo has 328.73 million shares outstanding. The number of shares has increased by 4.71% in one year.
| Current Share Class | 328.73M |
| Shares Outstanding | 328.73M |
| Shares Change (YoY) | +4.71% |
| Shares Change (QoQ) | +0.72% |
| Owned by Insiders (%) | 6.82% |
| Owned by Institutions (%) | 0.04% |
| Float | 282.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.80 |
| PB Ratio | -11.67 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.73
| Current Ratio | 0.73 |
| Quick Ratio | 0.61 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.61 |
| Interest Coverage | -22.47 |
Financial Efficiency
Return on equity (ROE) is -1,128.59% and return on invested capital (ROIC) is -169.02%.
| Return on Equity (ROE) | -1,128.59% |
| Return on Assets (ROA) | -118.09% |
| Return on Invested Capital (ROIC) | -169.02% |
| Return on Capital Employed (ROCE) | -951.05% |
| Weighted Average Cost of Capital (WACC) | 4.61% |
| Revenue Per Employee | 90,711 |
| Profits Per Employee | -321,911 |
| Employee Count | 46 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 6.57 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -55.75% in the last 52 weeks. The beta is -0.13, so BioLargo's price volatility has been lower than the market average.
| Beta (5Y) | -0.13 |
| 52-Week Price Change | -55.75% |
| 50-Day Moving Average | 0.11 |
| 200-Day Moving Average | 0.15 |
| Relative Strength Index (RSI) | 47.03 |
| Average Volume (20 Days) | 426,542 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.06 |
Income Statement
In the last 12 months, BioLargo had revenue of 4.08 million and -14.49 million in losses. Loss per share was -0.05.
| Revenue | 4.08M |
| Gross Profit | 1.63M |
| Operating Income | -18.11M |
| Pretax Income | -18.79M |
| Net Income | -14.49M |
| EBITDA | -17.95M |
| EBIT | -18.11M |
| Loss Per Share | -0.05 |
Balance Sheet
The company has 2.19 million in cash and 6.39 million in debt, with a net cash position of -4.21 million or -0.01 per share.
| Cash & Cash Equivalents | 2.19M |
| Total Debt | 6.39M |
| Net Cash | -4.21M |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | -2.73M |
| Book Value Per Share | -0.01 |
| Working Capital | -1.27M |
Cash Flow
In the last 12 months, operating cash flow was -10.32 million and capital expenditures -238,000, giving a free cash flow of -10.56 million.
| Operating Cash Flow | -10.32M |
| Capital Expenditures | -238,000 |
| Depreciation & Amortization | 157,000 |
| Net Borrowing | 3.23M |
| Free Cash Flow | -10.56M |
| FCF Per Share | -0.03 |
Margins
| Gross Margin | 39.91% |
| Operating Margin | -443.61% |
| Pretax Margin | -460.34% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioLargo does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.71% |
| Shareholder Yield | -4.71% |
| Earnings Yield | -45.48% |
| FCF Yield | -33.15% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioLargo has an Altman Z-Score of -40.1 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -40.1 |
| Piotroski F-Score | 1 |